Ardsley Advisory Partners’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Ardsley Advisory Partners’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-10,000	Closed	-$31K	–	216
2015 Q4	$31K	Sell	10,000 -5,000	-33%	-$22.5K	﹤0.01%	140
2015 Q3	$66K	Sell	15,000 -10,000	-40%	-$58.7K	0.02%	142
2015 Q2	$143K	Hold	25,000	–	–	0.02%	155
2015 Q1	$224K	Buy	+25,000	New	+$201K	0.03%	167

Other funds holding EPRS

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ardsley Advisory Partners's EPRS Position: Q1 2016 in Review

Ardsley Advisory Partners sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q1 2016, closing a stake of 10,000 shares — an estimated $31K sold.

Ardsley Advisory Partners first reported a position in EPRS in Q1 2015 and held it in 4 quarters. The position peaked at $224K in Q1 2015. 37 funds tracked by Wall St. Rank hold EPRS as of Q1 2016.

Ardsley Advisory Partners reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q1 2016 after selling out during the quarter.
Ardsley Advisory Partners sold 10,000 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q1 2016, an estimated $31K.
Ardsley Advisory Partners first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 4 quarters.
Ardsley Advisory Partners's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $224K in Q1 2015.
37 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q1 2016.

Based on Ardsley Advisory Partners's 13F filing for Q1 2016, filed 16 May 2016.